Search company, investor...

Blacksmith Medicines

blacksmithmedicines.com

Stage

Seed VC | Alive

About Blacksmith Medicines

Blacksmith Medicines is focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes.

Headquarters Location

10578 Science Center Drive Suite 205

San Diego, California, 92121,

United States

Missing: Blacksmith Medicines's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Blacksmith Medicines's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Blacksmith Medicines

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Blacksmith Medicines is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Blacksmith Medicines News

Blacksmith Medicines Raises Seed Funding

Jan 12, 2021

Blacksmith Medicines , a San Diego, CA-based , a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, raised a seed funding of undisclosed amount. The company has also entered into a research collaboration with Eli Lilly and Company (Lilly). Lilly joins existing investors Evotec A.G., MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. Under the terms of the research collaboration agreement, Blacksmith and Lilly will collaborate on up to 5 human metalloenzyme targets, with Blacksmith advancing novel small molecule inhibitors from fragment to ‘hit’ stage after which Lilly has the right to continue research, development, and commercialization. Blacksmith will receive an upfront payment and an investment from Lilly in exchange for a convertible note and will be eligible for up to approximately $60 million per target in potential research, development and commercial milestones for a total potential deal size up to approximately $300 million. A spin-out of Forge Therapeutics, an antibiotic discovery company discovering therapies to combat the rise of drug resistance, Blacksmith Medicines is advancing a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines. The Blacksmith metalloenzyme platform is a drug discovery engine purpose-built to target the largest and most diverse group of enzymes in the human genome. It has: A large proprietary fragment library of metal-binding pharmacophores (MBPs); A comprehensive database containing a full characterization of the metalloenzyme genome including functions, metal cofactors, and associations to disease; A metallo-CRISPR library of custom single guide RNAs; A metalloenzyme computational toolkit for docking, modeling and structure-based drug design; and A blocking intellectual property estate covering bioinorganic, medicinal, and computational chemistry approaches for metalloenzyme-targeted medicines. The company is led by Zachary Zimmerman, Ph.D., CEO. FinSMEs 12/01/2020

Blacksmith Medicines Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Blacksmith Medicines Rank

Blacksmith Medicines Frequently Asked Questions (FAQ)

  • Where is Blacksmith Medicines's headquarters?

    Blacksmith Medicines's headquarters is located at 10578 Science Center Drive, San Diego.

  • What is Blacksmith Medicines's latest funding round?

    Blacksmith Medicines's latest funding round is Seed VC.

  • Who are the investors of Blacksmith Medicines?

    Investors of Blacksmith Medicines include MP Healthcare Venture Management, Eli Lilly and Company, Evotec SE, Alexandria Venture Investments, MagnaSci Ventures and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.